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BORSA initially described non-
heteroresistant strains of S. aureus
with oxacillin MIC <2 mg/L, which
produce ample β-lactamases and are
rendered fully susceptible to PRP by
β-lactamase-inhibitors (4,6). Sub-
sequent BORSA strains described
have had higher oxacillin MICs (4–8
mg/L) (4). The proportion of BORSA
among clinical isolates of S. aureus
varies (1.4%–12.5%) but is usually
?5% (4,10). A BORSA infection out-
break among dermatology patients
with severe skin diseases has also
been reported (10). Postulated resist-
ance mechanisms include overpro-
duction of conventional penicillinas-
es, production of an inducible, plas-
mid-mediated, membrane-bound
methicillinase, and in some cases,
point mutations of penicillin-binding-
proteins (4). The clinical importance
of BORSA is unknown since early
clinical/animal data suggest treatment
efficacy of PRP (against strains with
MIC <2 mg/L) (4,6,9). Whether
BORSA with higher oxacillin MICs
(4–8 mg/L) will respond equally well
to PRP is less clear. Further studies
into the treatment of BORSA, includ-
ing pharmacokinetic considerations,
are needed (4). However, high-dose
β-lactam/β-lactamase inhibitor com-
binations (e.g., ampicillin/sulbactam),
as shown in animal models, are at
least as effective as PRP (9). In con-
clusion, our report suggests that mecA
(or PBP2a) detection may help man-
age serious, community-acquired,
non–multidrug-resistant MRSA infec-
tions because of the potential confu-
sion between BORSA and CA-
MRSA. 
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Rickettsia 
massiliae
Human Isolation
To the Editor: The number of new
rickettsial species that cause diseases
in humans is rapidly increasing (1).
Moreover, many of the species first
described in ticks have been recently
shown to be pathogenic. Of the 10
species or subspecies found to be
pathogens after 1984, a total of 7 were
first isolated from ticks (2). We report
the first isolation of Rickettsia massil-
iae from a patient. The bacterium was
isolated in Sicily in 1985 and identi-
fied in 2005.
A 45-year-old man was hospital-
ized in Palermo, Italy, on June 6,
1985, for fever and a rash. He had
been febrile since May 25 and did not
respond to antimicrobial drug treat-
ment using cefamezin, a first-genera-
tion cephalosporin. On examination,
he had a necrotic eschar on his right
ankle, a maculopapular rash on his
palms and soles (online Appendix
Figure 1, available at http://www.cdc.
gov/ncidod/EID/vol12no01/05-0850-
G1.htm), and slight hepatomegaly.
Leukocyte count was normal; he
received tetracyclines for 13 days and
fully recovered. He seroconverted
(from 0 to 1:80 between day 11 and
day 24) by indirect immunofluores-
cence to Rickettsia conorii (R. conorii
spot, bioMérieux, Marcy l’Étoile,
France).
Four milliliters of heparinized
blood sampled before treatment were
inoculated in a 25-cm2 flask contain-
ing Vero cells and incubated at 33°C
in a CO2 incubator (1). Direct
immunofluorescence test on a sample
of the patient’s serum was positive 7
days later. The strain was stored for
20 years and tested in 2005 at the
Unité des Rickettsies for identifica-
tion, and R. massiliae was identified.
DNA was extracted from the cell cul-
ture supernatant and used as template
in 2 previously described polymerase
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chain reaction (PCR) assays that tar-
geted a portion of the rickettsial
ompA gene as well as a portion of the
rickettsial gltA gene (3,4).
Amplification products of the expect-
ed size were obtained from this
extract but from no concurrently
processed control materials, includ-
ing 3 negative controls. DNA
sequencing of the positive PCR prod-
ucts gave 100% identity with R. mas-
siliae for ompA (GenBank accession
no. RBU43792) and 99.9% homolo-
gy for gltA (GenBank accession no.
RSU 59720).
R. massiliae was first isolated from
Rhipicephalus ticks in Marseilles (5).
It is transmitted transovarially in
Rhipicephalus turanicus (2). R. mas-
siliae is commonly found in
Rhipicephalus sanguineus or R.
turanicus in France, Greece, Spain
(identified as Bar 29) (6), Portugal,
Switzerland, Sicily (D. Raoult, unpub.
data), Central Africa, and Mali (2). R.
massiliae may be commonly associat-
ed with these ticks, which are distrib-
uted worldwide.
R. massiliae is grouped phylogeni-
cally with Rickettsia rhipicephali and
Rickettsia aeschlimannii (online
Appendix Figure 2, available at
http://www.cdc.gov/ncidod/EID/vol1
2no01/05-0850-G2.htm). Bacteria
from this group have a natural resist-
ance to rifampin that is associated
with an rpoB sequence that is differ-
ent from that of other rickettsiae. This
isolate was not tested for antimicro-
bial drug susceptibly (7). Rifampin
resistance leads us to believe that this
isolate may cause a Mediterranean
spotted fever–like disease that was
described in children in Spain (7,8).
Serologic findings were recently
reported that showed some patients in
Barcelona, Spain, with reactions that
indicate R. massiliae (B29 strain)
rather than R. conorii (6). However,
serologic reactions are only presump-
tive; isolation from a patient is the
required to initially describe a new
disease (9). 
This Sicilian index case shows that
R. massiliae is a human pathogen. It
contraindicates using rifampin to treat
Mediterranean spotted fever in areas
where R. massiliae is endemic, as it
cannot as yet be differentiated from R.
conorii infection. R. massiliae is a new
example of a strain identified in ticks
for several years before its first isola-
tion from a human patient (10). The
longest delay was observed for
Rickettsia parkeri, which was isolated
from ticks in 1939 but not from a
patient until 2004. Many authors
labeled R. parkeri a nonpathogenic
rickettsia during this time (1). In the
present case, the human isolate was
obtained before the tick isolate but
was not further identified. When this
strain was isolated, R. conorii was the
sole Rickettsia sp. found in ticks in
southern Europe. Moreover, only 1
tickborne pathogenic Rickettsia sp.
was believed to circulate in a single
area. Since that time, several tickborne
rickettsial diseases have been shown
to exist in the same area, which
prompted us to retrospectively identify
this strain. The patient was reexam-
ined in May 2005, after this identifica-
tion. He is healthy and has no remain-
ing antibodies against Rickettsia spp.
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